Zafirlukast (Standard)
Based on 1 Customer Validation
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.15%
- CAS No.: 107753-78-6
- Formule: C31H33N3O6S
- Masse moléculaire:575.68
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-17492
ZafirlukastLeukotriene Receptor Antagonist -
HY-19989A
MK-571 sodiumABCC1/MRP4 Inhibitor -
HY-13315
Montelukast sodiumCysltr1 Antagonist -
HY-B0290
PranlukastEndogenous Metabolite -
HY-13315A
MontelukastCysLT1 Antagonist -
HY-15744
LY255283LTB4 Receptor Antagonist -
HY-107608
Leukotriene B4PROTAC linker -
HY-19989
MK-571ABCC1/MRP4 Inhibitor -
HY-B0290R
Pranlukast (Standard)Endogenous Metabolite -
HY-13628
EtalocibLTB4 Receptor Antagonist -
HY-13315AR
Montelukast (Standard)CysLT1 Antagonist -
HY-19193
CP-105696LTB4 Receptor Antagonist
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 107753-78-6
-
Appearance Solid
-
Masse moléculaire 575.68
-
Formule C31H33N3O6S
-
Color White to off-white
-
SMILES
O=C(OC1CCCC1)NC2=CC3=C(N(C)C=C3CC4=CC=C(C(NS(=O)(C5=CC=CC=C5C)=O)=O)C=C4OC)C=C2
-
Synonyms
ICI 204219 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Finnerty JP, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746-9. [Content Brief]
[2]. Gunning WT, et al. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201. [Content Brief]
[3]. Lei C, et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int Immunopharmacol. 2019;68:68-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zafirlukast (Standard) Related Classifications
HY-17492R Related Classifications
Powered by Bioz